Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma
Wendan Xu, Ji-Won Kim, Woo June Jung, Youngil Koh, Sung-Soo Yoon
Cancer Res Treat. 2018;50(2):599-613.   Published online 2017 Jun 19     DOI:
Citations to this article as recorded by Crossref logo
Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
Yuan Wang, Jing He, Manyu Xu, Qingfeng Xue, Cindy Zhu, Juan Liu, Yaping Zhang, Wenyu Shi
Frontiers in Oncology.2022;[Epub]     CrossRef
Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
Juanjuan Xiao, Lu Zhang, Huijun Yi, Ling Zou, Jianmei Mo, Feng Xue, Jinhua Zheng, Yingze Huang, Hui Lu, Hansheng Wu, Peipei Xue, Xin Zhang, Lifei He, Zhaoxin Li, Shigui Pang, Guibin Qiao, Qiuhong Duan, Feng Zhu
Cell Death & Disease.2022;[Epub]     CrossRef
CORR Insights®: Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma
Xiaodong Tang
Clinical Orthopaedics & Related Research.2021; 479(4): 853.     CrossRef
Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of breast cancer cells via downregulation of MET and estrogen receptor
Nehad M. Ayoub, Amer E. Alkhalifa, Dalia R. Ibrahim, Ahmed Alhusban
Medical Oncology.2021;[Epub]     CrossRef
The Dual Role of Autophagy in Crizotinib-Treated ALK+ ALCL: From the Lymphoma Cells Drug Resistance to Their Demise
Estelle Espinos, Raymond Lai, Sylvie Giuriato
Cells.2021; 10(10): 2517.     CrossRef
Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
Caiyu Lin, Hengyi Chen, Rui Han, Li Li, Conghua Lu, Shuai Hao, Yubo Wang, Yong He
Thoracic Cancer.2021; 12(23): 3184.     CrossRef